NO870368D0 - Fremgangsmaate for fremstilling av et farmasoeytisk preparat med langvarig virkning. - Google Patents

Fremgangsmaate for fremstilling av et farmasoeytisk preparat med langvarig virkning.

Info

Publication number
NO870368D0
NO870368D0 NO870368A NO870368A NO870368D0 NO 870368 D0 NO870368 D0 NO 870368D0 NO 870368 A NO870368 A NO 870368A NO 870368 A NO870368 A NO 870368A NO 870368 D0 NO870368 D0 NO 870368D0
Authority
NO
Norway
Prior art keywords
preparing
procedure
long
pharmaceutical preparation
term effect
Prior art date
Application number
NO870368A
Other languages
English (en)
Other versions
NO174325C (no
NO174325B (no
NO870368L (no
Inventor
Calum Brechin Macfarlane
Alistair Brereton Selkirk
Michael John Dey
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of NO870368D0 publication Critical patent/NO870368D0/no
Publication of NO870368L publication Critical patent/NO870368L/no
Publication of NO174325B publication Critical patent/NO174325B/no
Publication of NO174325C publication Critical patent/NO174325C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/82—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO870368A 1986-01-30 1987-01-29 Fremgangsmåte for fremstilling av sfæroider som inneholder kalsiumblokker NO174325C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82389686A 1986-01-30 1986-01-30
US94087886A 1986-12-10 1986-12-10

Publications (4)

Publication Number Publication Date
NO870368D0 true NO870368D0 (no) 1987-01-29
NO870368L NO870368L (no) 1987-07-31
NO174325B NO174325B (no) 1994-01-10
NO174325C NO174325C (no) 1994-04-20

Family

ID=27124769

Family Applications (1)

Application Number Title Priority Date Filing Date
NO870368A NO174325C (no) 1986-01-30 1987-01-29 Fremgangsmåte for fremstilling av sfæroider som inneholder kalsiumblokker

Country Status (18)

Country Link
EP (1) EP0231026B1 (no)
JP (1) JP2524990B2 (no)
KR (1) KR900005009B1 (no)
AU (1) AU604672B2 (no)
CA (1) CA1285227C (no)
DE (1) DE3782439T2 (no)
DK (1) DK175216B1 (no)
ES (1) ES2052500T3 (no)
FI (1) FI88872C (no)
GR (1) GR3006148T3 (no)
HU (1) HU196709B (no)
IE (1) IE61879B1 (no)
IL (2) IL81419A0 (no)
IT (1) IT1206876B (no)
NO (1) NO174325C (no)
NZ (1) NZ219090A (no)
PH (1) PH26366A (no)
PT (1) PT84213B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940556A (en) * 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
IT1227336B (it) * 1987-09-11 1991-04-08 Squibb & Sons Inc Composizione farmaceutica contenente un carico elevato di medicamento e procedimento per la sua preparazione
JP2528706B2 (ja) * 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
US4925676A (en) * 1989-02-02 1990-05-15 Warner-Lambert Company Extended release gemfibrozil composition
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
JPH0729926B2 (ja) * 1989-07-25 1995-04-05 大塚製薬株式会社 易吸収性製剤用組成物
CA2126441C (en) * 1991-12-30 1999-12-21 David F. Erkoboni Microcrystalline cellulose spheronization composition
GB9203689D0 (en) * 1992-02-20 1992-04-08 Euro Celtique Sa Pharmaceutical composition
DE69311394T2 (de) * 1992-02-20 1997-10-30 Euro Celtique Sa Arzneimittel verzögerter Wirkstoffabgabe
HRP970485A2 (en) * 1996-09-13 1998-08-31 Joerg Rosenberg Process for producing solid pharmaceutical forms
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
EP1027885B1 (en) * 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US8481565B2 (en) 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795766A (fr) * 1972-02-22 1973-08-22 Lilly Co Eli Particules de napsylate de propoxyphene retard et procede de fabrication de ces particules
JPS5846019A (ja) * 1981-09-14 1983-03-17 Kanebo Ltd 持続性ニフエジピン製剤
FR2581541B1 (fr) * 1985-05-09 1988-05-20 Rhone Poulenc Sante Nouvelles compositions pharmaceutiques permettant la liberation prolongee d'un principe actif et leur procede de preparation

Also Published As

Publication number Publication date
PT84213B (pt) 1989-03-30
DE3782439D1 (de) 1992-12-10
DE3782439T2 (de) 1993-05-19
GR3006148T3 (no) 1993-06-21
PH26366A (en) 1992-06-01
HU196709B (en) 1989-01-30
DK47787A (da) 1987-07-31
CA1285227C (en) 1991-06-25
NO174325C (no) 1994-04-20
KR900005009B1 (ko) 1990-07-16
IE61879B1 (en) 1994-11-30
AU6810287A (en) 1987-08-06
KR870007121A (ko) 1987-08-17
JP2524990B2 (ja) 1996-08-14
NO174325B (no) 1994-01-10
IE870229L (en) 1987-07-30
JPS62252732A (ja) 1987-11-04
IT1206876B (it) 1989-05-11
PT84213A (en) 1987-02-01
IT8767057A0 (it) 1987-01-29
IL81419A (en) 1991-07-18
FI88872C (fi) 1993-07-26
FI870380A (fi) 1987-07-31
IL81419A0 (en) 1987-08-31
AU604672B2 (en) 1991-01-03
ES2052500T3 (es) 1994-07-16
NZ219090A (en) 1990-04-26
EP0231026A1 (en) 1987-08-05
DK175216B1 (da) 2004-07-12
EP0231026B1 (en) 1992-11-04
HUT42950A (en) 1987-09-28
FI870380A0 (fi) 1987-01-29
FI88872B (fi) 1993-04-15
DK47787D0 (da) 1987-01-29
NO870368L (no) 1987-07-31

Similar Documents

Publication Publication Date Title
NO885641L (no) Fremgangsmaate for fremstilling av farmasoeytisk preparat.
NO882103L (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat
NO173213C (no) Fremgangsmaate for fremstilling av et preparat omfattende et liposom
NO871790L (no) Fremgangsmaate for fremstilling av et oralt farmasoeytisk preparat.
NO880410L (no) Oralt preparat.
NO903264D0 (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat i form av mikropartikler.
NO873562D0 (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat med forbedret absorpsjon av sulindac.
NO874347D0 (no) Fremgangsmaate for fremstilling av insulin.
NO934897D0 (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat
NO170912C (no) Fremgangsmaate for fremstilling av en fast, holdbar administreringsform
IS3339A7 (is) Ný efnablanda lyfja
NO870368D0 (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat med langvarig virkning.
FI852804A0 (fi) Farmaceutiska preparat med reglerbar utloesning.
NO884052D0 (no) Fremgangsmaate for fremstilling av et terapeutisk preparat.
NO173590C (no) Fremgangsmaate for fremstilling av et stabilt nikorandilholdig farmasoeytisk preparat
NO156153C (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat med langvarig frigjoering.
NO901232L (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat
FI822187L (fi) Farmaceutiska preparat
NO870866L (no) Fremgangsmÿte for fremstilling av et terapeutisk kombinasjonspreparat.
FI874382A (fi) Farmaceutiska preparat.
NO890330D0 (no) Fremgangsmaate til fremstilling av forbindelser med psykotrop virkning.
NO873571D0 (no) Fremgangsmaate for fremstilling av et terapeutisk virksomt preparat.
NO874539D0 (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat
NO903442D0 (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat med regulert biologisk tilgjengelighet.
NO911964L (no) Fremgangsmaate for fremstilling av et stabilt preparat.